Candid Therapeutics Acquired by UCB for up to $2.2 Billion
Cooley advised Candid Therapeutics, a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), on its agreement to be acquired by UCB, a global biopharmaceutical company, for up to $2.2 billion.
The transaction was announced publicly in the following press release, which can be viewed here.
Lead team: M&A lawyers Rama Padmanabhan, Lindsey O’Crump and Rajdeep Bains and corporate lawyers Carlos Ramirez and Charlie Kim led the Cooley team advising Candid Therapeutics.
Supporting team: Jenny Ge, Brittany Wightman, Sharon Connaughton, Stephanie Gentile, Todd Gluth, Alessandra Murata, Marya Postner, John Forrest, Joanna Zhang and John DelMastro provided invaluable support.
Cooley previously advised Candid Therapeutics on its now terminated reverse merger with Rallybio in early 2026, as well as its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004 in 2024.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.